ALSO NOTED: Nigeria wants to extradite U.S. Pfizerites; PDI BioPharma sells cardio drugs;

> Just weeks after Nigerian officials sent local Pfizer officials scurrying to avoid arrest, the Kano state government is asking that three Americans be extradited and tried in the ongoing court battle over a meningitis drug trial there. Report

> PDI BioPharma agreed to sell its FDA-approved cardiovascular meds Cardene and Retavase for up to $170 million; the deal also includes an in-development drug called ularitide. Report

> In 2007, Cephalon spent $160,000 lobbying for the approval and insurance reimbursement of Vivitrol, a treatment for alcoholism, according to Senate documents. Report

> Alkermes announced that its Risperidone antipsychotic drug helps to prevent relapse in patients with bipolar disorder, according to a new study. Report

> Though nearly one in four primary care docs prescribe antidepressants for lower back pain, there's no evidence the drugs offer relief, according to a new study. Report

> Extending antiretroviral treatment to HIV-positive moms who are breastfeeding helps keep babies from contracting the virus via their mothers' milk. Report

> Researchers have overcome one of the chief obstacles to developing a vaginal gel to protect poor women from HIV infection. Report

> Researchers targeting new treatments for the common cold can now look forward to getting help from a new mouse model for the ailment. Report

> Struggling under the weight of falling anemia drug sales, Amgen is selling the Japanese rights to a slate of some 13 experimental therapies to Takeda in a deal that may be worth more than $1 billion. Report

> Wanted: Biotech companies with no cash flow, facing a high risk and in need of money to back translational development efforts. Report

And Finally... Eat your veggies, avoid saturated fat, and take aspirin? New research shows that long-term use of the pain killer cut the risk of colon cancer by up to 70 percent. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.